Improving Outcomes in Pancreatic Cancer With Perioperative mFOLFIRINOX

September 26, 2017
Davendra Sohal, MD, MPH

Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the need for an ongoing study exploring mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.